Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment | Zendy

Gjin Ndrepepa | Zendy; Franz–Josef Neumann | Zendy; Efthymios Deliargyris | Zendy; Roxana Mehran | Zendy; Julinda Mehilli | Zendy; Mirosław Ferenc | Zendy; S. Schulz | Zendy; Albert Schömig | Zendy; Adnan Kastrati | Zendy; Gregg W. Stone | Zendy

Open Access

Bivalirudin Versus Heparin Plus a Glycoprotein IIb/IIIa Inhibitor in Patients With Non–ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention After Clopidogrel Pretreatment

Author(s) -

Gjin Ndrepepa,

Franz–Josef Neumann,

Efthymios Deliargyris,

Roxana Mehran,

Julinda Mehilli,

Mirosław Ferenc,

S. Schulz,

Albert Schömig,

Adnan Kastrati,

Gregg W. Stone

Publication year - 2012

Publication title -

circulation cardiovascular interventions

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.621

H-Index - 95

eISSN - 1941-7632

pISSN - 1941-7640

DOI - 10.1161/circinterventions.112.972869

Subject(s) - bivalirudin , medicine , percutaneous coronary intervention , clopidogrel , myocardial infarction , cardiology , heparin , antithrombotic , anesthesia

The optimal antithrombotic therapy for patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention is not well defined. We investigated the efficacy and safety of bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor (GPI) in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research